3 completed, 1 terminated, 1 withdrawn. 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Gd-DOTA: new trials by email Literature Review of Gd-DOTA trials Research Report on Gd-DOTA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging - Glioma | Completed | OHSU Knight Cancer Institute | 4 | 2023-12-11 | 2026-06-05 | |
| QSM and Regional DCE MRI Permeability Using GOCART Technique Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine - Intracranial Neoplasm | Withdrawn | University of Southern California | 2017-04-04 | 2021-04-05 | ||
| Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age Gadoteric Acid - Adverse Reaction to Drug, Allergic Reaction to Contrast Media | Completed | St. Louis University | 150 | 2016-01-01 | 2019-09-13 | |
| Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) Calcium EDTA, Gd-DOTA - Renal Insufficiency, Chronic, Kidney Diseases | Phase 1 / Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 166 | 2014-10-01 | 2018-05-18 |
| Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease Dotarem, Gadovist - Peripheral Arterial Disease | Phase 4 | Completed | Guerbet | 189 | 2009-10-01 | 2012-12-11 |
Brain Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Glioma (1) · Kidney Diseases (1) · Peripheral Arterial Disease (1) · Renal Insufficiency, Chronic (1)
Assistance Publique - Hôpitaux de Paris (1) · Guerbet (1) · OHSU Knight Cancer Institute (1) · St. Louis University (1) · University of Southern California (1)
United States (3) · Austria (1) · France (1)
Alexander Lerner (1) · Marie Courbebaisse, Doctor (1) · Martin Pike, Ph.D. (1) · Shannon Farmakis, MD (1)
P30CA014089 (1)